Open Label Extension for GLYX13-C-202, NCT01684163

NCT02192099 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

61

Enrollment

INDUSTRY

Sponsor class

Stopped Patients from this study were rolled into RAP-MD-99.

Conditions

Major Depressive Disorder

Interventions

DRUG: Rapastinel (225 mg/450 mg IV administration)

Sponsor

Naurex, Inc, an affiliate of Allergan plc